Even less in the Seven Bucks wheelhouse (and devoid of a Johnson performance) is an upcoming documentary feature about ...

Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating ...

Johnson & Johnson faces uncertainty with speculation about RFK Jr. at HHS. Learn why JNJ stock remains a buy despite ...

"Johnson & Johnson MedTech announces partnership for soft tissue solutions" was originally created and published by Medical ...

Chris Della Rocca will oversee J&J's corporate business technology strategy, which includes finance and legal, and report to ...

Biolojic Design, a biotechnology company that uses computational biology and artificial intelligence (AI) to transform antibodies into programmable, intelligent medicines, today announced that it is ...

Terence Flynn, an analyst from Morgan Stanley, maintained the Hold rating on Johnson & Johnson (JNJ – Research Report). The associated ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Johnson & Johnson (NYSE:JNJ) with a Outperform ...

However, HRSA resisted the plan, threatening to terminate Johnson & Johnson’s PPA and impose significant penalties. This ...

Johnson & Johnson (JNJ) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Johnson & Johnson MedTech announced today that it entered into an exclusive commercial distribution agreement with Responsive Arthroscopy.

NEWARK, CA / ACCESSWIRE / November 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the company will host a conference call and webcast to announce its ...